Patients with newly diagnosed peripheral T cell lymphomas (PTCLs) responded significantly well to the anti-CD30 antibody–drug combination brentuximab vedotin (BV), indicating that CD30 is an acceptable target for these subtypes of lymphoma. The gene discussed is TNFRSF8; the disease is lymphoma.